Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454571 | 0.80 | CTSC (0.34) | — | |
| SCHEMBL27512005 | 0.68 | OPRD1 (0.82) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6797795 | 0.68 | OPRD1 (1.00) | OPRD1OPRM1OPRK1ALDH1A1HPGD | |
| SCHEMBL3468776 | 0.67 | OPRD1 (0.48) | OPRD1OPRM1OPRK1ALDH1A1MAPT | |
| SCHEMBL27476085 | 0.67 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| SCHEMBL27501405 | 0.67 | OPRD1 (0.80) | OPRD1OPRM1OPRK1 | |
| SCHEMBL12736121 | 0.66 | OPRD1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL27474131 | 0.65 | OPRD1 (0.75) | OPRD1OPRM1OPRK1 | |
| SCHEMBL27473306 | 0.64 | OPRD1 (0.73) | OPRD1OPRM1OPRK1 | |
| SCHEMBL27485227 | 0.63 | OPRD1 (0.79) | OPRD1OPRM1OPRK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2166850-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | High Point Pharmaceuticals, LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |